Jonas Mandel

723 total citations
13 papers, 408 citations indexed

About

Jonas Mandel is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Neurology. According to data from OpenAlex, Jonas Mandel has authored 13 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 4 papers in Endocrinology, Diabetes and Metabolism and 3 papers in Neurology. Recurrent topics in Jonas Mandel's work include Lipoproteins and Cardiovascular Health (8 papers), Diabetes Treatment and Management (4 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Jonas Mandel is often cited by papers focused on Lipoproteins and Cardiovascular Health (8 papers), Diabetes Treatment and Management (4 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Jonas Mandel collaborates with scholars based in France, United States and United Kingdom. Jonas Mandel's co-authors include Helen M. Colhoun, Maja Bujas‐Bobanovic, Lawrence A. Leiter, Rita Samuel, Alexia Letierce, Francisco J. Tinahones, Stefano Del Prato, Catherine Domenger, Andrew Koren and Kausik K. Ray and has published in prestigious journals such as PLoS ONE, Kidney International and European Heart Journal.

In The Last Decade

Jonas Mandel

12 papers receiving 403 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonas Mandel France	9	271	119	104	71	50	13	408
Joshua Miles United States	9	209 0.8×	66 0.6×	34 0.3×	51 0.7×	31 0.6×	14	320
Marisa Schoen United States	7	140 0.5×	49 0.4×	38 0.4×	7 0.1×	41 0.8×	10	369
Valérie Carreau France	13	364 1.3×	54 0.5×	150 1.4×	10 0.1×	77 1.5×	22	502
Naganand Sripathi United States	7	158 0.6×	14 0.1×	19 0.2×	49 0.7×	52 1.0×	16	382
Sastry Prayaga United States	7	132 0.5×	20 0.2×	69 0.7×	16 0.2×	104 2.1×	9	341
Mohamed Naceur Slimane Tunisia	14	211 0.8×	14 0.1×	107 1.0×	20 0.3×	69 1.4×	28	459
Federico Bigazzi Italy	12	256 0.9×	31 0.3×	90 0.9×	8 0.1×	150 3.0×	47	462
Vincent Lenain Switzerland	8	180 0.7×	7 0.1×	129 1.2×	29 0.4×	34 0.7×	9	394
Tony Sabin United Kingdom	10	22 0.1×	23 0.2×	43 0.4×	23 0.3×	8 0.2×	11	349
Guangzhong Chen China	10	87 0.3×	9 0.1×	12 0.1×	11 0.2×	21 0.4×	23	333

Countries citing papers authored by Jonas Mandel

Since Specialization

Citations

This map shows the geographic impact of Jonas Mandel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonas Mandel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonas Mandel more than expected).

Fields of papers citing papers by Jonas Mandel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonas Mandel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonas Mandel. The network helps show where Jonas Mandel may publish in the future.

Co-authorship network of co-authors of Jonas Mandel

This figure shows the co-authorship network connecting the top 25 collaborators of Jonas Mandel. A scholar is included among the top collaborators of Jonas Mandel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonas Mandel. Jonas Mandel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Nabirotchkin, Serguei, Jonas Mandel, Julie Foucquier, et al.. (2022). Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer’s Disease. Journal of Alzheimer s Disease. 88(4). 1585–1603.

Vallejo‐Vaz, Antonio J., Lawrence A. Leiter, Stefano Del Prato, et al.. (2020). Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. European Journal of Preventive Cardiology. 27(15). 1663–1674. 5 indexed citations

Ray, Kausik K., Stefano Del Prato, Dirk Müller‐Wieland, et al.. (2019). Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Cardiovascular Diabetology. 18(1). 149–149. 27 indexed citations

Tóth, Peter P., Jamie P. Dwyer, Christopher P. Cannon, et al.. (2018). Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney International. 93(6). 1397–1408. 79 indexed citations

Leiter, Lawrence A., Francisco J. Tinahones, Dean G. Karalis, et al.. (2018). Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabetic Medicine. 35(12). 1742–1751. 19 indexed citations

McCullough, Peter A., Christie M. Ballantyne, Santosh K. Sanganalmath, et al.. (2018). Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). The American Journal of Cardiology. 121(8). 940–948. 14 indexed citations

Ganda, Om P., Jorge Plutzky, Santosh K. Sanganalmath, et al.. (2018). Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials. Diabetes Obesity and Metabolism. 20(10). 2389–2398. 17 indexed citations

Leiter, Lawrence A., Bertrand Cariou, Dirk Müller‐Wieland, et al.. (2017). Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial. Diabetes Obesity and Metabolism. 19(12). 1781–1792. 100 indexed citations

Harvey, Philip D., Marwan N. Sabbagh, John Harrison, et al.. (2017). No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data. European Heart Journal. 39(5). 374–381. 54 indexed citations

10.

Dwyer, Jamie P., Helen M. Colhoun, Francisco J. Tinahones, et al.. (2016). Abstract 16850: Effect of Alirocumab in Patients With Diabetic Dyslipidemia and Chronic Kidney Disease. 134. 1 indexed citations

11.

Mandel, Jonas, Viviane Bertrand, Philippe Lehert, et al.. (2015). A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment. Orphanet Journal of Rare Diseases. 10(1). 74–74. 15 indexed citations

12.

Wang, Wenjia, Jonas Mandel, Daniel Commenges, et al.. (2015). A Multi-Marker Genetic Association Test Based on the Rasch Model Applied to Alzheimer’s Disease. PLoS ONE. 10(9). e0138223–e0138223. 6 indexed citations

13.

Chumakov, Ilya, Aude Milet, Nathalie Cholet, et al.. (2014). Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orphanet Journal of Rare Diseases. 9(1). 201–201. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact